Em­bold­ened by AS­CO da­ta, FDA etch­es speedy ap­proval path for Io­vance's cer­vi­cal can­cer ther­a­py

Io­vance’s promis­ing da­ta snap­shot de­tail­ing the po­ten­tial of its cer­vi­cal can­cer drug at AS­CO has con­vinced the FDA to ac­cel­er­ate its path to ap­proval.

On Tues­day, the drug de­vel­op­er said the US reg­u­la­tor has rec­om­mend­ed that an on­go­ing mid-stage study of its ex­per­i­men­tal ther­a­py may be suf­fi­cient to sup­port an ap­pli­ca­tion to mar­ket LN-145 in pa­tients with ad­vanced cer­vi­cal can­cer.

“This feed­back is en­cour­ag­ing. The abil­i­ty to use the cur­rent study, as well as the Break­through Ther­a­py des­ig­na­tion re­cent­ly grant­ed to LN-145, al­lows us to plan on a path to BLA sub­mis­sion in the sec­ond half of 2020,” Io­vance chief Maria Fardis said in a state­ment. The com­pa­ny’s shares climbed about 2.6% to $25.26 be­fore the bell.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER